Cardium Therapeutics, Inc. (CXM) Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy Of Generx® Angiogenic Gene Therapy For Myocardial Ischemia Due To Coronary Artery Disease At The 2014 Biotechnology Industry Organization (BIO) International Convention
6/24/2014 10:11:37 AM
SAN DIEGO--(BUSINESS WIRE)--Taxus Cardium Pharmaceuticals Group Inc. (OTCQB: CRXM) will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx® Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. The presentation at the 2014 BIO International Convention, now underway at the San Diego Convention Center, will be by Christopher Reinhard, Taxus Cardium’s Chief Executive Officer and Cardium Therapeutics’ co-founder, at 4:30 pm June 24 in the Mission Beach room.
Help employers find you! Check out all the jobs and post your resume.
comments powered by